The National Agency for Food and Drug Administration and Control says it will continue hydroxychloroquine clinical trials for the treatment of COVID-19 in Nigeria despite the suspension of the same by the World Health Organization.

NAFDAC Director-General, Professor MOJISOLA ADEYEYE, made this known during a monitored programme.

Professor ADEYEYE said there are proven records that hydroxychloroquine had been effective in the treatment of COVID-19 patients, especially those at the “mild stage” of the virus.

The NAFDAC DG, who said Lagos State had already begun hydroxychloroquine clinical trials, noted that depending on the speed of work, the clinical trials should conclude in three to four months.